Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying specific stocks in the market. We monitor 13F filings and institutional buying patterns because large investors often have superior information and research capabilities. We provide ownership data, fund flow analysis, and institutional positioning for comprehensive coverage. Follow institutional money with our comprehensive ownership tracking and analysis tools for smarter investment decisions.
As of 2026-04-09, Replimune Group Inc. (REPL) is trading at $6.16, posting a 4.59% gain on the session amid mixed broader market activity. This analysis, aligned with recent market coverage of REPL, explores key technical levels, recent trading context, and potential near-term scenarios for the clinical-stage biotechnology firm, which focuses on developing oncolytic immunotherapies for cancer treatment. No recent earnings data is available for REPL at the time of writing, so short-term price act
Is Replimune Group (REPL) Stock cyclical or stable | Price at $6.16, Up 4.59% - Real Trader Insights
REPL - Stock Analysis
3722 Comments
850 Likes
1
Waldon
Trusted Reader
2 hours ago
The market shows a balance of buying and selling pressure, leading to sideways movement.
👍 73
Reply
2
Brookeann
Active Contributor
5 hours ago
Markets are reacting cautiously to economic data releases.
👍 236
Reply
3
Shiyah
Expert Member
1 day ago
Short-term fluctuations suggest that active management is required for traders focusing on intraday moves.
👍 217
Reply
4
Jaydeep
Elite Member
1 day ago
This feels like something important just happened.
👍 254
Reply
5
Ysobel
Active Reader
2 days ago
So late to the party… 😭
👍 244
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.